Skip to main content
Beijing Luzhu Biotechnology Co., Ltd. logo

Beijing Luzhu Biotechnology Co., Ltd. — Investor Relations & Filings

Ticker · 2480 HKEX Manufacturing
Open in API
Filings indexed 128 across all filing types
Latest filing 2026-05-05 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2480

About Beijing Luzhu Biotechnology Co., Ltd.

http://www.luzhubiotech.com

Beijing Luzhu Biotechnology Co., Ltd. is a biotechnology company specializing in the research, development, production, and commercialization of innovative human vaccines and therapeutic biologics, including bispecific antibody drugs. The company's pipeline targets disease prevention and treatment, addressing significant clinical needs. Its core product is the recombinant Herpes Zoster Vaccine (LZ901). LZ901 has achieved positive immunogenicity and safety data in head-to-head clinical trials against a leading market competitor, with findings published in Nature Communications. The Biologics License Application (BLA) for LZ901 has been accepted by the National Medical Products Administration (NMPA). Luzhu Biotechnology employs a strategy combining proprietary R&D with the integration of advanced international technologies.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings
2026-05-05 English
Annual Report 2025
Annual Report Classification · 1% confidence The document is explicitly titled 'Annual Report' for the year 2025, issued by Beijing Luzhu Biotechnology Co., Ltd. It contains comprehensive sections including corporate information, financial highlights, management discussion and analysis, auditor's report, and consolidated financial statements. It meets all criteria for a full annual report. FY 2025
2026-04-23 English
CHANGE IN USE OF PROCEEDS
Capital/Financing Update Classification · 1% confidence The document is a formal stock exchange announcement by Beijing Luzhu Biotechnology Co., Ltd. regarding a board resolution to change the use of unutilized net proceeds from its previous global offering. It is not an AGM presentation, annual or interim report, earnings release, or audit report; instead it provides an update on capital raised (the Global Offering) and how those funds will be reallocated. This fits the “Capital/Financing Update” category (CAP).
2026-04-23 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 1% confidence The document is a standard HKEX monthly return (Form FF301) reporting movements in authorised share capital, issued shares, treasury shares and public float confirmation under the Exchange’s Listing Rules. It is not announcing an AGM, earnings, capital raising, share issue event or financial results, nor is it a management discussion or full report. It is a routine regulatory filing required by the exchange. Therefore it best fits the fallback category “Regulatory Filings” (RNS).
2026-04-02 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
Annual Report Classification · 1% confidence The document is an 'Annual Results Announcement' for Beijing Luzhu Biotechnology Co., Ltd. for the year ended December 31, 2025. It contains audited consolidated financial statements, including the statement of profit or loss, statement of financial position, and detailed notes to the financial statements. While it is titled an 'Announcement', it provides the full scope of annual financial reporting required for a listed company on the Hong Kong Stock Exchange, which qualifies it as an Annual Report (10-K equivalent in this context). FY 2025
2026-03-18 English
ANNOUNCEMENT - CHANGE OF JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT
Board/Management Information Classification · 1% confidence The document is an official announcement from Beijing Luzhu Biotechnology Co., Ltd. regarding the resignation and appointment of a joint company secretary, authorized representative, and process agent. This type of corporate change involving board-level or senior management support roles falls under the 'Board/Management Information' category.
2026-03-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.